Key Points
- CEO Randy Teel sold 4,786 shares on Feb. 23 at an average price of $12.16 for $58,197.76, reducing his stake by 3.10% to 149,696 shares, according to the SEC filing.
- Q4 earnings miss: Arvinas reported EPS of -$1.10 versus a -$0.55 consensus and revenue of $9.5M versus $37.26M (down 84% YoY), a primary catalyst pressuring the stock.
- Outlook and sentiment are mixed: Management says it has a cash runway into the second half of 2028 and highlighted 2026 clinical milestones for its PROTAC pipeline, but analysts remain divided (consensus "Hold" with a $13.47 target while some firms see upside to $20).
Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) CAO David Loomis sold 1,108 shares of the business's stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $12.16, for a total value of $13,473.28. Following the completion of the sale, the chief accounting officer owned 29,692 shares in the company, valued at $361,054.72. This represents a 3.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Arvinas Price Performance
NASDAQ:ARVN traded down $0.16 on Thursday, reaching $13.14. 248,695 shares of the company's stock were exchanged, compared to its average volume of 805,538. The firm has a market cap of $844.04 million, a price-to-earnings ratio of -10.27 and a beta of 1.88. The stock has a fifty day simple moving average of $12.40 and a 200-day simple moving average of $10.53. Arvinas, Inc. has a 52 week low of $5.90 and a 52 week high of $18.93.
Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($1.10) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.55). The business had revenue of $9.50 million for the quarter, compared to analysts' expectations of $37.26 million. Arvinas had a negative net margin of 30.77% and a negative return on equity of 13.22%. The business's quarterly revenue was down 84.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.63) earnings per share. As a group, sell-side analysts predict that Arvinas, Inc. will post -3.81 EPS for the current year.
Trending Headlines about Arvinas
Here are the key news stories impacting Arvinas this week:
- Positive Sentiment: Piper Sandler reiterated an "overweight" rating and raised its price target to $20, signaling significant upside from current levels. Piper Sandler raises PT to $20
- Positive Sentiment: Company guidance and commentary: Arvinas outlined 2026 clinical-data milestones and said it maintains a cash runway into the second half of 2028, which reduces near-term financing risk and supports ongoing pipeline programs. Arvinas outlines 2026 milestones & cash runway
- Positive Sentiment: Sector/pipeline coverage: Recent media coverage highlighted Arvinas' promising PROTAC pipeline, which helped the stock move higher in futures earlier in the session. Coverage: Promising pipeline lifts futures
- Neutral Sentiment: Consensus/ratings: The consensus analyst view remains mixed — the street average is a "Hold," so upgrades like Piper Sandler's may not represent unanimous enthusiasm. Analyst consensus: Hold
- Neutral Sentiment: Short-interest data appears unreliable in the latest report (shows 0 shares and NaN). Given the data anomaly, short-squeeze/read-through risk is unclear until corrected figures are released. (No external link — data report entry)
- Negative Sentiment: Q4 earnings/revenue miss: Arvinas reported a sizable EPS and revenue shortfall for Q4 2025 — EPS missed estimates and revenue fell sharply year-over-year — which is the primary catalyst pressuring the stock. Q4 2025 earnings call transcript
- Negative Sentiment: Insider selling: CEO Randy Teel sold 4,786 shares and CAO David K. Loomis sold 1,108 shares on Feb 23, modestly reducing their holdings; such sales can be perceived negatively by investors even if they may be routine. CEO filing: CEO Form 4 — CAO filing: CAO Form 4
Analysts Set New Price Targets
ARVN has been the topic of a number of analyst reports. Wells Fargo & Company decreased their target price on shares of Arvinas from $16.00 to $15.00 and set an "overweight" rating on the stock in a report on Thursday, November 6th. Stephens upped their price target on shares of Arvinas from $14.00 to $15.00 and gave the stock an "overweight" rating in a report on Monday, November 10th. Citigroup raised Arvinas from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $10.00 to $15.00 in a research note on Tuesday, January 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arvinas in a report on Monday, December 22nd. Finally, Piper Sandler reiterated an "overweight" rating and set a $20.00 price target (up from $16.00) on shares of Arvinas in a research report on Wednesday. Ten investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Arvinas presently has a consensus rating of "Hold" and a consensus target price of $13.47.
Check Out Our Latest Analysis on ARVN
Hedge Funds Weigh In On Arvinas
A number of large investors have recently modified their holdings of ARVN. Invesco Ltd. grew its position in Arvinas by 26.9% during the fourth quarter. Invesco Ltd. now owns 302,100 shares of the company's stock valued at $3,583,000 after acquiring an additional 64,044 shares during the last quarter. Corient Private Wealth LLC bought a new stake in shares of Arvinas in the 4th quarter worth approximately $127,000. State of Tennessee Department of Treasury purchased a new stake in shares of Arvinas in the 4th quarter valued at $323,000. Ikarian Capital LLC grew its holdings in shares of Arvinas by 58.3% during the 4th quarter. Ikarian Capital LLC now owns 358,257 shares of the company's stock valued at $4,249,000 after purchasing an additional 132,000 shares during the last quarter. Finally, Voloridge Investment Management LLC purchased a new position in Arvinas in the 4th quarter worth $1,079,000. 95.19% of the stock is owned by hedge funds and other institutional investors.
Arvinas Company Profile
(
Get Free Report)
Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body's natural protein-recycling systems.
The company's most advanced clinical candidates address hormone-driven cancers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
